Form 4: Progyny Director Norman Payson Reports Stock Transactions

Progyny, Inc. Director Norman Payson reported transactions involving restricted stock units and stock options on May 21, 2026.

Summary

• Norman Payson, a Director at Progyny, Inc., reported the acquisition of 5,660 shares of common stock underlying restricted stock units (RSUs) on May 21, 2026.
• Payson also acquired stock options to purchase 3,203 shares at an exercise price of $24.69 and another 27,119 shares at the same exercise price, both on May 21, 2026.
• These RSUs and stock options are subject to vesting conditions, typically on May 21, 2027, or the day before the issuer's first annual meeting of stockholders following the grant date, contingent on continued service.
• Following these transactions, Payson beneficially owns 12,349 shares directly, with additional holdings of 331,363 shares indirectly through The Norman C. and Melinda B. Payson Revocable Trust and 122,493 shares indirectly through EVO Eagle, LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it primarily details routine equity awards to a director, indicating ongoing compensation and alignment, rather than significant strategic shifts or financial performance indicators.

Positives

• Director Norman Payson acquired a significant number of shares through RSUs and stock options, indicating continued alignment with the company's performance.
• The acquisition of stock options at an exercise price of $24.69 suggests a belief in future stock price appreciation beyond this level.
• Indirect beneficial ownership through trusts and LLCs indicates broader stakeholder interest and potential long-term commitment.

Negatives

• The filing details acquisitions, not disposals, so there are no immediate negative financial implications from selling shares.
• The vesting conditions for RSUs and options mean that the full benefit is not immediately realized, introducing a time-based risk.

Risks

• The value of the acquired RSUs and stock options is contingent on the continued service of Norman Payson and the future performance of Progyny, Inc.'s stock.
• Vesting schedules introduce a risk that the full benefit of the awards may not be realized if service conditions are not met.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a forward-looking perspective, with benefits tied to continued service and company performance over the next several years.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving directors acquiring equity, are common in the health benefits management sector as a way to align executive interests with shareholder value. Progyny operates in a competitive market, and such transactions can signal confidence from leadership.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director can be seen as a positive signal of confidence in the company's future prospects.
• Employees: The transaction is part of the executive compensation structure, indirectly impacting employee morale and retention through leadership incentives.
• Management: Reinforces the alignment of director compensation with company performance and long-term value creation.

Next Steps

• Vesting of RSUs and stock options on May 21, 2027, or the day before the issuer's first annual meeting of stockholders, subject to continued service.
• Potential exercise of stock options after vesting, depending on market conditions and the reporting person's strategy.

Key Dates

Keywords

Progyny, PGNY, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, Beneficial Ownership, SEC Filing, Securities Transaction